Sara Moslehi, Zahra Sadat Mahmoodian, Sasan Zandi Esfahan
Introduction: The rising impact of osteoporosis and fragility fractures highlights the need for advanced management strategies. Integrating digital health interventions, especially artificial intelligence (AI) algorithms, is essential. Osteoporosis, a major contributor to elderly disability, demands AI to minimize diagnostic errors. This review targets stakeholders interested in employing AI for osteoporosis management. Methods: We examined 16 articles from PubMed, Google Scholar, and Medline (January 1, 2015, to January 1, 2023) using keywords like AI, osteoporosis, fragility fracture, and machine learning. After excluding redundancies, 15 articles were selected, covering five key aspects of osteoporosis management: Bone mineral densitometry (BMD) predictive variables (n=1), diagnosis, screening, and classification of osteoporosis (n=5), diagnosis and screening of fractures (n=4), fracture risk forecast (n=2), and automated image segmentation (n=3). Results: Recent machine learning (ML) advances empower AI in assessing bone health beyond X-rays. Techniques, including AI-driven analysis with multi-detector computed tomography scans, extend beyond X-ray imaging. Convolutional neural networks (CNNs) excel in fracture diagnosis, surpassing medical professionals. Enhanced CNN performance is achieved through data augmentation and generative networks. Conclusion: Initial ML applications in osteoporosis research focus on the macroscopic scale, leaving a gap in microscale exploration. Establishing a robust system for bone micro-damage initiation detection is crucial for future applications in bone micromechanics. Ongoing development is essential to assess effectiveness and affordability through controlled studies.
简介：骨质疏松症和脆性骨折的影响日益严重，凸显了对先进管理策略的需求。整合数字健康干预措施，尤其是人工智能（AI）算法至关重要。骨质疏松症是导致老年人残疾的一个主要因素，需要人工智能来最大限度地减少诊断错误。本综述针对有兴趣将人工智能用于骨质疏松症管理的利益相关者。研究方法我们使用人工智能、骨质疏松症、脆性骨折和机器学习等关键词，对PubMed、谷歌学术和Medline（2015年1月1日至2023年1月1日）上的16篇文章进行了研究。在剔除冗余内容后，选出了 15 篇文章，涵盖骨质疏松症管理的五个关键方面：骨密度测量（BMD）预测变量（n=1），骨质疏松症的诊断、筛查和分类（n=5），骨折的诊断和筛查（n=4），骨折风险预测（n=2），以及自动图像分割（n=3）。结果：近期机器学习（ML）的进步使人工智能在评估骨骼健康方面的能力超越了 X 射线。包括人工智能驱动的多探头计算机断层扫描分析在内的各种技术已经超越了 X 射线成像。卷积神经网络（CNN）在骨折诊断方面表现出色，超过了医疗专业人员。通过数据增强和生成网络，增强了卷积神经网络的性能。结论骨质疏松症研究中最初的 ML 应用侧重于宏观尺度，在微观尺度的探索方面存在空白。建立一个强大的骨微观损伤启动检测系统对于未来骨微观力学的应用至关重要。持续开发对于通过对照研究评估有效性和经济性至关重要。
{"title":"Types of application of artificial intelligence in the diagnosis and prognosis of osteoporosis; a narrative review","authors":"Sara Moslehi, Zahra Sadat Mahmoodian, Sasan Zandi Esfahan","doi":"10.34172/jpd.2024.11245","DOIUrl":"https://doi.org/10.34172/jpd.2024.11245","url":null,"abstract":"Introduction: The rising impact of osteoporosis and fragility fractures highlights the need for advanced management strategies. Integrating digital health interventions, especially artificial intelligence (AI) algorithms, is essential. Osteoporosis, a major contributor to elderly disability, demands AI to minimize diagnostic errors. This review targets stakeholders interested in employing AI for osteoporosis management. Methods: We examined 16 articles from PubMed, Google Scholar, and Medline (January 1, 2015, to January 1, 2023) using keywords like AI, osteoporosis, fragility fracture, and machine learning. After excluding redundancies, 15 articles were selected, covering five key aspects of osteoporosis management: Bone mineral densitometry (BMD) predictive variables (n=1), diagnosis, screening, and classification of osteoporosis (n=5), diagnosis and screening of fractures (n=4), fracture risk forecast (n=2), and automated image segmentation (n=3). Results: Recent machine learning (ML) advances empower AI in assessing bone health beyond X-rays. Techniques, including AI-driven analysis with multi-detector computed tomography scans, extend beyond X-ray imaging. Convolutional neural networks (CNNs) excel in fracture diagnosis, surpassing medical professionals. Enhanced CNN performance is achieved through data augmentation and generative networks. Conclusion: Initial ML applications in osteoporosis research focus on the macroscopic scale, leaving a gap in microscale exploration. Establishing a robust system for bone micro-damage initiation detection is crucial for future applications in bone micromechanics. Ongoing development is essential to assess effectiveness and affordability through controlled studies.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141278010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tertiary hyperparathyroidism is a condition characterized by excessive production of parathyroid hormone (PTH) by the parathyroid glands, leading to increased calcium levels in the blood. It typically occurs in patients with long-standing secondary hyperparathyroidism, often as a result of chronic kidney disease (CKD). The primary treatment goal for tertiary hyperparathyroidism is to normalize PTH levels and maintain calcium and phosphorus balance. This typically involves the use of medications to control hypercalcemia and hyperphosphatemia. Calcimimetic agents, such as cinacalcet, can help lower PTH levels by increasing the sensitivity of the calcium-sensing receptors on the parathyroid glands. Additionally, phosphate binders can be prescribed to reduce serum phosphate levels.
{"title":"Recent advancements in the treatment of tertiary hyperparathyroidism","authors":"Parisa Tajdini, Simin Mazaheri Tehrani, Yasaman Vahdani","doi":"10.34172/jpd.2024.11259","DOIUrl":"https://doi.org/10.34172/jpd.2024.11259","url":null,"abstract":"Tertiary hyperparathyroidism is a condition characterized by excessive production of parathyroid hormone (PTH) by the parathyroid glands, leading to increased calcium levels in the blood. It typically occurs in patients with long-standing secondary hyperparathyroidism, often as a result of chronic kidney disease (CKD). The primary treatment goal for tertiary hyperparathyroidism is to normalize PTH levels and maintain calcium and phosphorus balance. This typically involves the use of medications to control hypercalcemia and hyperphosphatemia. Calcimimetic agents, such as cinacalcet, can help lower PTH levels by increasing the sensitivity of the calcium-sensing receptors on the parathyroid glands. Additionally, phosphate binders can be prescribed to reduce serum phosphate levels.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"76 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141278316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The adverse clinical implications of vitamin D (vitD) deficiency in hemodialysis (HD) patients are widespread and include bone mineral disorders, cardiovascular disease, infections, and mortality. For example, low vitD values are connected with a heightened risk of fractures, osteomalacia, and secondary hyperparathyroidism. Additionally, low vitD levels have been linked to increased arterial stiffness, left ventricular hypertrophy, and heart failure in HD patients. Moreover, vitD deficiency has been connected with an intensified risk of infections, particularly respiratory tract infections, in HD patients. Finally, multiple studies have found an association between low vitD levels and increased mortality in HD patients.
血液透析（HD）患者缺乏维生素 D（vitD）的不良临床影响非常广泛，包括骨矿物质紊乱、心血管疾病、感染和死亡。例如，维生素 D 值过低会增加骨折、骨软化症和继发性甲状旁腺功能亢进的风险。此外，维生素 D 含量低还与高密度脂蛋白血症患者动脉僵化、左心室肥大和心力衰竭加剧有关。此外，维生素 D 缺乏还与 HD 患者感染风险增加有关，尤其是呼吸道感染。最后，多项研究发现，维生素 D 水平低与 HD 患者死亡率升高有关。
{"title":"Vitamin D status in hemodialysis; current opinions","authors":"Parisa Tajdini, Sadaf Farnam Nia, Nabiha Midhat Ansari, Maryam Farahmandsadr","doi":"10.34172/jpd.2024.11260","DOIUrl":"https://doi.org/10.34172/jpd.2024.11260","url":null,"abstract":"The adverse clinical implications of vitamin D (vitD) deficiency in hemodialysis (HD) patients are widespread and include bone mineral disorders, cardiovascular disease, infections, and mortality. For example, low vitD values are connected with a heightened risk of fractures, osteomalacia, and secondary hyperparathyroidism. Additionally, low vitD levels have been linked to increased arterial stiffness, left ventricular hypertrophy, and heart failure in HD patients. Moreover, vitD deficiency has been connected with an intensified risk of infections, particularly respiratory tract infections, in HD patients. Finally, multiple studies have found an association between low vitD levels and increased mortality in HD patients.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141279299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Parathyroid crisis (storm), also known as parathyroid storm, is an extremely rare and life-threatening endocrine emergency caused by excessive secretion of parathyroid hormone (PTH). It is characterized by sudden and severe hypercalcemia, which can lead to multi-organ dysfunction and failure. This review paper aims to provide an in-depth understanding of parathyroid crisis, including its pathophysiology, clinical presentation, diagnosis, and management options.
{"title":"Parathyroid crisis; a short look at an uncommon disease","authors":"Parisa Tajdini, Simin Mazaheri Tehrani, Yasaman Vahdani","doi":"10.34172/jpd.2024.11261","DOIUrl":"https://doi.org/10.34172/jpd.2024.11261","url":null,"abstract":"Parathyroid crisis (storm), also known as parathyroid storm, is an extremely rare and life-threatening endocrine emergency caused by excessive secretion of parathyroid hormone (PTH). It is characterized by sudden and severe hypercalcemia, which can lead to multi-organ dysfunction and failure. This review paper aims to provide an in-depth understanding of parathyroid crisis, including its pathophysiology, clinical presentation, diagnosis, and management options.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"57 46","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141275025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Behairy, Sahar Mahmoud Shawky, Somia Abdelhamid Bawady, H. Abdelsattar, Neveen Nabil Abdelsahheed, Ahmad Yehia Elhag
Introduction: Secondary hyperparathyroidism (SHPT) is a common complication associated with morbidity and mortality among hemodialysis (HD) patients. Objectives: The current study aims to evaluate the frequency of CASR gene polymorphism variants related to parathyroid hormone (PTH) regulation (CASR rs1042636 and CASR rs1802757) and to test the hypothesis that single nucleotide polymorphisms (SNPs) in the CASR gene alter the response to cinacalcet among Egyptian HD patients with SHPT. Patients and Methods: A case-control study that included 50 HD patients with intact parathyroid hormone (iPTH) ≥300 pg/mL treated with cinacalcet for a 6-month duration and 40 healthy volunteers as a control group. Eligible patients were recruited from Ain Shams university hospitals. Blood samples were collected from patients and controls to assess allele frequencies of CASR gene polymorphism variants using real-time polymerase chain reaction (PCR), corrected calcium (Ca), phosphorus (P), Ca×P product, iPTH level, and alkaline phosphatase before and after treatment. HD patients were categorized into two groups based on the reduction percentage; responders’ patients (iPTH ≥20%) and non-responders to cinacalcet treatment. Results: Of 50 HD patients, 48 (96%) carried the rs1042636 AA wild gene, while only two (4%) carried the rs1042636 AG mutant gene, 42 (87.5%) carried the rs1802757 CC wild genotype, and 6 (12.5%) carried the CT mutant genotype. The minor alleles T and G were (6.3% and 2%) respectively, with no statistically significant difference between the patient and control groups regarding the CASR genotypes or alleles distribution. There was no significant difference between responders and non-responder’s patient groups regarding CASR genotypes or allele frequencies. Moreover, no significant correlation between CASR genotypes or alleles to delta change of Ca, P, Ca×P product, or PTH was seen. However, CASR rs1802757 CT mutant genotype was associated with a significant reduction in alkaline phosphatase levels after treatment. Conclusion: There is no significant association between the gene polymorphism CASR rs1042636 or CASR rs1802757 and the reduction in PTH levels as a response to cinacalcet treatment among Egyptian HD patients with SHPT.
简介：继发性甲状旁腺功能亢进症（SHPT）是血液透析（HD）患者中一种常见的并发症，与发病率和死亡率相关。研究目的本研究旨在评估与甲状旁腺激素（PTH）调节相关的 CASR 基因多态性变异（CASR rs1042636 和 CASR rs1802757）的频率，并检验 CASR 基因中的单核苷酸多态性（SNPs）是否会改变患有 SHPT 的埃及 HD 患者对西那卡塞的反应这一假设。患者和方法：病例对照研究：50 名甲状旁腺激素（iPTH）≥ 300 pg/mL 的 HD 患者接受为期 6 个月的西那卡塞治疗，40 名健康志愿者作为对照组。符合条件的患者来自艾因夏姆斯大学医院。采集患者和对照组的血样，使用实时聚合酶链式反应（PCR）评估 CASR 基因多态性变异的等位基因频率、治疗前后的校正钙（Ca）、磷（P）、Ca×P 乘积、iPTH 水平和碱性磷酸酶。根据降低的百分比将 HD 患者分为两组：对西那卡西酮治疗有反应的患者（iPTH ≥20%）和无反应的患者。结果在 50 名 HD 患者中，48 人（96%）携带 rs1042636 AA 野生基因，只有 2 人（4%）携带 rs1042636 AG 突变基因，42 人（87.5%）携带 rs1802757 CC 野生基因型，6 人（12.5%）携带 CT 突变基因型。小等位基因 T 和 G 的比例分别为 6.3% 和 2%，在 CASR 基因型或等位基因分布方面，患者组和对照组之间没有显著的统计学差异。在 CASR 基因型或等位基因频率方面，有反应和无反应患者组之间没有明显差异。此外，CASR基因型或等位基因与Ca、P、Ca×P乘积或PTH的δ变化之间也没有明显的相关性。不过，CASR rs1802757 CT 突变基因型与治疗后碱性磷酸酶水平的明显降低有关。结论在患有 SHPT 的埃及 HD 患者中，CASR rs1042636 或 CASR rs1802757 基因多态性与 PTH 水平的降低（对西那卡西特治疗的反应）之间没有明显关联。
{"title":"Relationship of calcium-sensing receptor gene polymorphism CASR rs 1042636, CASR rs 1802757, and cinacalcet response among Egyptian hemodialysis patients with secondary hyperparathyroidism","authors":"M. Behairy, Sahar Mahmoud Shawky, Somia Abdelhamid Bawady, H. Abdelsattar, Neveen Nabil Abdelsahheed, Ahmad Yehia Elhag","doi":"10.34172/jpd.2024.11255","DOIUrl":"https://doi.org/10.34172/jpd.2024.11255","url":null,"abstract":"Introduction: Secondary hyperparathyroidism (SHPT) is a common complication associated with morbidity and mortality among hemodialysis (HD) patients. Objectives: The current study aims to evaluate the frequency of CASR gene polymorphism variants related to parathyroid hormone (PTH) regulation (CASR rs1042636 and CASR rs1802757) and to test the hypothesis that single nucleotide polymorphisms (SNPs) in the CASR gene alter the response to cinacalcet among Egyptian HD patients with SHPT. Patients and Methods: A case-control study that included 50 HD patients with intact parathyroid hormone (iPTH) ≥300 pg/mL treated with cinacalcet for a 6-month duration and 40 healthy volunteers as a control group. Eligible patients were recruited from Ain Shams university hospitals. Blood samples were collected from patients and controls to assess allele frequencies of CASR gene polymorphism variants using real-time polymerase chain reaction (PCR), corrected calcium (Ca), phosphorus (P), Ca×P product, iPTH level, and alkaline phosphatase before and after treatment. HD patients were categorized into two groups based on the reduction percentage; responders’ patients (iPTH ≥20%) and non-responders to cinacalcet treatment. Results: Of 50 HD patients, 48 (96%) carried the rs1042636 AA wild gene, while only two (4%) carried the rs1042636 AG mutant gene, 42 (87.5%) carried the rs1802757 CC wild genotype, and 6 (12.5%) carried the CT mutant genotype. The minor alleles T and G were (6.3% and 2%) respectively, with no statistically significant difference between the patient and control groups regarding the CASR genotypes or alleles distribution. There was no significant difference between responders and non-responder’s patient groups regarding CASR genotypes or allele frequencies. Moreover, no significant correlation between CASR genotypes or alleles to delta change of Ca, P, Ca×P product, or PTH was seen. However, CASR rs1802757 CT mutant genotype was associated with a significant reduction in alkaline phosphatase levels after treatment. Conclusion: There is no significant association between the gene polymorphism CASR rs1042636 or CASR rs1802757 and the reduction in PTH levels as a response to cinacalcet treatment among Egyptian HD patients with SHPT.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"49 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140434059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cinacalcet has emerged as an effective therapeutic option for the management of secondary hyperparathyroidism (SHPT) and chronic kidney disease-mineral and bone disorder (CKD-MBD). Through its modulation of the calcium-sensing receptor (CaSR), cinacalcet demonstrates considerable clinical benefits in maintaining parathyroid hormone and serum calcium levels within target ranges. It offers a valuable addition to the available treatment options for patients with these conditions. Cinacalcet binds to the CaSR on parathyroid cells, increasing its sensitivity to extracellular calcium. This results in decreased parathyroid hormone (PTH; parathormone), release through inhibition of intracellular signaling pathways involved in PTH synthesis and secretion. Cinacalcet also indirectly reduces serum calcium and phosphorus levels by suppressing PTH-mediated bone resorption and enhancing renal phosphate excretion.
{"title":"Clinical administration of cinacalcet in parathyroid diseases","authors":"Azadeh Khayyat, Mohammad Ali Esmaeil pour","doi":"10.34172/jpd.2024.11256","DOIUrl":"https://doi.org/10.34172/jpd.2024.11256","url":null,"abstract":"Cinacalcet has emerged as an effective therapeutic option for the management of secondary hyperparathyroidism (SHPT) and chronic kidney disease-mineral and bone disorder (CKD-MBD). Through its modulation of the calcium-sensing receptor (CaSR), cinacalcet demonstrates considerable clinical benefits in maintaining parathyroid hormone and serum calcium levels within target ranges. It offers a valuable addition to the available treatment options for patients with these conditions. Cinacalcet binds to the CaSR on parathyroid cells, increasing its sensitivity to extracellular calcium. This results in decreased parathyroid hormone (PTH; parathormone), release through inhibition of intracellular signaling pathways involved in PTH synthesis and secretion. Cinacalcet also indirectly reduces serum calcium and phosphorus levels by suppressing PTH-mediated bone resorption and enhancing renal phosphate excretion.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"61 15","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140453612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mohammad Ali Esmaeil pour, P. Kaviani, Azadeh Khayyat
Nephrologists and endocrinologists work closely together in the diagnosis, treatment planning, and management of complications, surgical intervention, and also long-term management of parathyroid diseases. Their collaboration ensures holistic care for patients, addressing both the endocrine and nephrological aspects of the condition.
{"title":"Parathyroid disease; a bridge between nephrologist and endocrinologist","authors":"Mohammad Ali Esmaeil pour, P. Kaviani, Azadeh Khayyat","doi":"10.34172/jpd.2024.11251","DOIUrl":"https://doi.org/10.34172/jpd.2024.11251","url":null,"abstract":"Nephrologists and endocrinologists work closely together in the diagnosis, treatment planning, and management of complications, surgical intervention, and also long-term management of parathyroid diseases. Their collaboration ensures holistic care for patients, addressing both the endocrine and nephrological aspects of the condition.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"38 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140487725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Areeb Ansari, Kamran Shirbache, Ali Shirbacheh, Hamid Nasri
Several studies have found a clear association between higher PTH levels and increased mortality risk in hemodialysis patients. The studies indicate that higher levels of PTH are linked to a higher risk of cardiovascular events, such as heart attacks and strokes, as well as an increased risk of bone fractures.
{"title":"Parathyroid hormone level predicts mortality in hemodialysis; an old problem remains still","authors":"Areeb Ansari, Kamran Shirbache, Ali Shirbacheh, Hamid Nasri","doi":"10.34172/jpd.2024.11247","DOIUrl":"https://doi.org/10.34172/jpd.2024.11247","url":null,"abstract":"Several studies have found a clear association between higher PTH levels and increased mortality risk in hemodialysis patients. The studies indicate that higher levels of PTH are linked to a higher risk of cardiovascular events, such as heart attacks and strokes, as well as an increased risk of bone fractures.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":" 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139623630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ladan Hajiabdolrrasouli, H. Samimagham, S. Hosseini Teshnizi, Ali Salimi Asl, MohammadHosein Sheybani-Arani, Soroush Jaberansari, Mitra Kazemi Jahromi
Introduction: Due to the possibility of malignancy of thyroid nodules, it is necessary to identify the type of thyroid nodule to choose the most accurate treatment possible. Objectives: Considering that there is no standard diagnostic method for masses with intermediate suspicion of malignancy, the present study was conducted to investigate the diagnostic value of ultrasound in differentiating between benign and malignant thyroid masses compared with fine needle aspiration (FNA). Patients and Methods: In this cross-sectional study, 150 patients who had been referred to an endocrinologist’s office in Bandar Abbas with a complaint of thyroid mass in 2019-2020 and had undergone ultrasound and FNA were included in the study by census. After obtaining their informed consent, the patient’s information was collected by reviewing their ultrasound and FNA reports and analyzed with descriptive and analytical tests in SPSS software version 26. Results: The sensitivity and specificity of ultrasound in detecting malignant and benign masses were 56.25% and 85.07%, respectively. The positive and negative predictive values of ultrasound were 60% and 98.27%, respectively. The number of malignant FNA reports was significantly higher in the intermediate suspicion category of patients than in patients with ultrasound results showing high suspicion of malignancy. Conclusion: Performing further diagnostic measures such as FNA and core needle biopsy after noticing an intermediate suspicion in a patient’s ultrasound seems necessary.
{"title":"Comparing ultrasound to fine needle aspiration in differentiating between benign and malignant thyroid masses","authors":"Ladan Hajiabdolrrasouli, H. Samimagham, S. Hosseini Teshnizi, Ali Salimi Asl, MohammadHosein Sheybani-Arani, Soroush Jaberansari, Mitra Kazemi Jahromi","doi":"10.34172/jpd.2024.11244","DOIUrl":"https://doi.org/10.34172/jpd.2024.11244","url":null,"abstract":"Introduction: Due to the possibility of malignancy of thyroid nodules, it is necessary to identify the type of thyroid nodule to choose the most accurate treatment possible. Objectives: Considering that there is no standard diagnostic method for masses with intermediate suspicion of malignancy, the present study was conducted to investigate the diagnostic value of ultrasound in differentiating between benign and malignant thyroid masses compared with fine needle aspiration (FNA). Patients and Methods: In this cross-sectional study, 150 patients who had been referred to an endocrinologist’s office in Bandar Abbas with a complaint of thyroid mass in 2019-2020 and had undergone ultrasound and FNA were included in the study by census. After obtaining their informed consent, the patient’s information was collected by reviewing their ultrasound and FNA reports and analyzed with descriptive and analytical tests in SPSS software version 26. Results: The sensitivity and specificity of ultrasound in detecting malignant and benign masses were 56.25% and 85.07%, respectively. The positive and negative predictive values of ultrasound were 60% and 98.27%, respectively. The number of malignant FNA reports was significantly higher in the intermediate suspicion category of patients than in patients with ultrasound results showing high suspicion of malignancy. Conclusion: Performing further diagnostic measures such as FNA and core needle biopsy after noticing an intermediate suspicion in a patient’s ultrasound seems necessary.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":" 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139623477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Azar Baradaran, Padideh Daneii, Mahshid Imankhan, Mahsa Motieian, Sina Neshat
Prospects in parathyroid diseases involve a multidisciplinary approach that combines research, clinical practice, and patient-centered care to improve understanding, diagnosis, and treatment outcomes for individuals with these conditions. Accordingly, further advancements in genetics, biomarkers, imaging, targeted therapies, non-surgical treatments, and personalized medicine can potentially revolutionize diagnosing, treating, and managing parathyroid diseases.
{"title":"Future prospects in parathyroid diseases","authors":"Azar Baradaran, Padideh Daneii, Mahshid Imankhan, Mahsa Motieian, Sina Neshat","doi":"10.34172/jpd.2023.11240","DOIUrl":"https://doi.org/10.34172/jpd.2023.11240","url":null,"abstract":"Prospects in parathyroid diseases involve a multidisciplinary approach that combines research, clinical practice, and patient-centered care to improve understanding, diagnosis, and treatment outcomes for individuals with these conditions. Accordingly, further advancements in genetics, biomarkers, imaging, targeted therapies, non-surgical treatments, and personalized medicine can potentially revolutionize diagnosing, treating, and managing parathyroid diseases.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135958015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：